|
|
Volumn 18, Issue 3, 2015, Pages 376-378
|
|
A commentary on a recent update of the ovarian cancer risk attributable to menopausal hormone therapy
|
|
Author keywords
Absolute risk; Estrogen therapy; Estrogen progestin combined therapy; Menopause; Ovarian cancer
|
|
Indexed keywords
CANCER RISK;
ESTROGEN THERAPY;
FEMALE;
HORMONAL THERAPY;
HUMAN;
MENOPAUSE;
MORTALITY;
ORAL CONTRACEPTION;
OVARY CANCER;
PRIORITY JOURNAL;
PROSPECTIVE STUDY;
RETROSPECTIVE STUDY;
REVIEW;
RISK FACTOR;
ADVERSE EFFECTS;
AGED;
DRUG EFFECTS;
FRANCE;
META ANALYSIS (TOPIC);
MIDDLE AGED;
OVARIAN NEOPLASMS;
RISK ASSESSMENT;
UNITED KINGDOM;
UNITED STATES;
VERY ELDERLY;
ESTROGEN;
AGED;
AGED, 80 AND OVER;
ESTROGEN REPLACEMENT THERAPY;
ESTROGENS;
FEMALE;
FRANCE;
GREAT BRITAIN;
HUMANS;
MENOPAUSE;
META-ANALYSIS AS TOPIC;
MIDDLE AGED;
OVARIAN NEOPLASMS;
RISK ASSESSMENT;
UNITED STATES;
|
|
EID: 84929317332
PISSN: 13697137
EISSN: 14730804
Source Type: Journal
DOI: 10.3109/13697137.2015.1023615 Document Type: Review |
|
Times cited : (9)
|
|
References (8)
|
